JP2016528202A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016528202A5 JP2016528202A5 JP2016524930A JP2016524930A JP2016528202A5 JP 2016528202 A5 JP2016528202 A5 JP 2016528202A5 JP 2016524930 A JP2016524930 A JP 2016524930A JP 2016524930 A JP2016524930 A JP 2016524930A JP 2016528202 A5 JP2016528202 A5 JP 2016528202A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament according
- administered
- vegf antagonist
- disorder
- child
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361845064P | 2013-07-11 | 2013-07-11 | |
| US61/845,064 | 2013-07-11 | ||
| PCT/IB2014/062978 WO2015004616A1 (en) | 2013-07-11 | 2014-07-09 | Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016528202A JP2016528202A (ja) | 2016-09-15 |
| JP2016528202A5 true JP2016528202A5 (enExample) | 2017-08-10 |
Family
ID=51211282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524930A Pending JP2016528202A (ja) | 2013-07-11 | 2014-07-09 | 小児患者の脈絡網膜血管新生障害および透過性障害の治療におけるｖｅｇｆアンタゴニストの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20160168240A1 (enExample) |
| EP (1) | EP3019526A1 (enExample) |
| JP (1) | JP2016528202A (enExample) |
| KR (1) | KR20160029794A (enExample) |
| CN (1) | CN105377891A (enExample) |
| AU (2) | AU2014288837A1 (enExample) |
| BR (1) | BR112016000177A2 (enExample) |
| CA (1) | CA2917807A1 (enExample) |
| MX (1) | MX2016000384A (enExample) |
| RU (1) | RU2676274C2 (enExample) |
| WO (1) | WO2015004616A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3252079B8 (en) | 2006-04-07 | 2020-09-09 | Aerpio Therapeutics LLC | Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| SG10201505672TA (en) | 2009-07-06 | 2015-09-29 | Aerpio Therapeutics Inc | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| CN104039351A (zh) | 2011-10-13 | 2014-09-10 | 阿尔皮奥治疗学股份有限公司 | 用于治疗血管渗漏综合征和癌症的方法 |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| EP3116503A4 (en) | 2014-03-14 | 2017-08-23 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
| EP3828202A1 (en) * | 2014-05-12 | 2021-06-02 | Formycon AG | Pre-filled plastic syringe containing a vegf antagonist |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| EP3352856B1 (en) | 2015-09-23 | 2021-08-18 | Aerpio Pharmaceuticals, Inc. | Activators of tie-2 for use in treating intraocular pressure |
| US20180326126A1 (en) * | 2015-11-18 | 2018-11-15 | Formycon Ag | Pre-filled plastic syringe containing a vegf antagonist |
| EP3377101A4 (en) * | 2015-11-19 | 2019-08-07 | Zhuhai Tairuishang Biopharm Ltd. | VEGF BINDING METHODS AND COMPOSITIONS |
| BR112018013407A2 (en) | 2015-12-30 | 2018-12-18 | Kodiak Sciences Inc. | antibodies and conjugates thereof |
| US10654922B2 (en) * | 2016-05-13 | 2020-05-19 | Askgene Pharma Inc. | Angiopoietin 2, VEGF dual antagonists |
| WO2018017714A1 (en) | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| TW201836646A (zh) * | 2017-01-25 | 2018-10-16 | 美商艾康尼醫療股份有限公司 | 治療與血管生成及血管新生相關病症的方法 |
| EP3618923A1 (en) * | 2017-05-01 | 2020-03-11 | Ojai Retinal Technology, LLC | System and process for treatment of myopia |
| MX2020005142A (es) * | 2017-11-16 | 2021-01-15 | Iveric Bio Inc | Un método para tratar o prevenir la vasculopatía coroidal polipoidal idiopática (ipcv). |
| SG11202008242XA (en) | 2018-03-02 | 2020-09-29 | Kodiak Sciences Inc | Il-6 antibodies and fusion constructs and conjugates thereof |
| US11253502B2 (en) | 2019-04-29 | 2022-02-22 | EyePoint Pharmaceuticals, Inc. | Tie-2 activators targeting the Schlemm's canal |
| KR20250051157A (ko) | 2019-06-05 | 2025-04-16 | 리제너론 파아마슈티컬스, 인크. | 정밀 투여량 전달을 위한 디바이스 및 방법 |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| JP7730816B2 (ja) * | 2019-12-19 | 2025-08-28 | アクティブ バイオテック エービー | 過剰血管新生に関連する眼疾患を治療する化合物 |
| RU2762991C1 (ru) * | 2021-09-06 | 2021-12-24 | федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ лечения макулярного отека вследствие окклюзии ветви центральной вены сетчатки в сочетании с ретинальной артериолярной макроаневризмой |
| TW202525324A (zh) * | 2023-08-17 | 2025-07-01 | 大陸商信達生物製藥（蘇州）有限公司 | 治療年齡相關性黃斑變性和糖尿病性黃斑水腫的方法 |
| CN118085112B (zh) * | 2024-04-29 | 2024-08-09 | 上海鼎新基因科技有限公司 | 抗多个vegf家族蛋白的融合蛋白及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60239868D1 (de) | 2001-06-12 | 2011-06-09 | Univ Johns Hopkins Med | Reservoirvorrichtung für die intraokulare arzneimittelabgabe |
| US20050244472A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intraocular drug delivery systems containing excipients with reduced toxicity and related methods |
| KR100897379B1 (ko) | 2004-06-08 | 2009-05-14 | 쳉두 캉홍 바이오테크놀로지스 코. 리미티드 | 혈관신생-저해 키메릭 단백질 및 그 사용 |
| US20070072933A1 (en) * | 2005-09-26 | 2007-03-29 | Peyman Gholam A | Delivery of an ocular agent |
| US8039010B2 (en) | 2006-11-03 | 2011-10-18 | Allergan, Inc. | Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
| BRPI0908502A2 (pt) * | 2008-02-21 | 2017-05-23 | Ista Pharmaceuticals | aines oftálmicos como adjuvantes |
| US8535681B2 (en) * | 2008-10-16 | 2013-09-17 | Kathleen Cogan Farinas | Sustained drug delivery system |
| EP2358746B1 (en) * | 2008-11-03 | 2020-09-16 | Molecular Partners AG | Binding proteins inhibiting the vegf-a receptor interaction |
| CN102325550B (zh) * | 2008-12-16 | 2016-10-26 | Qlt公司 | 光动力学疗法和抗vegf剂在治疗有害的脉络膜新血管系统中的联合应用 |
| CN104887389B (zh) | 2009-01-29 | 2017-06-23 | 弗赛特影像4股份有限公司 | 后段给药 |
| EP3028707A1 (en) * | 2009-05-01 | 2016-06-08 | Ophthotech Corporation | Methods for treating or preventing ophthalmological diseases |
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質 |
| RU2469734C2 (ru) * | 2010-09-02 | 2012-12-20 | Григорий Владимирович Пантелеев | Лечебное средство для лечения расстройств аккомодаций "stiak" |
-
2014
- 2014-07-09 US US14/903,749 patent/US20160168240A1/en not_active Abandoned
- 2014-07-09 AU AU2014288837A patent/AU2014288837A1/en not_active Abandoned
- 2014-07-09 KR KR1020167000239A patent/KR20160029794A/ko not_active Withdrawn
- 2014-07-09 CN CN201480039606.4A patent/CN105377891A/zh active Pending
- 2014-07-09 BR BR112016000177A patent/BR112016000177A2/pt not_active IP Right Cessation
- 2014-07-09 WO PCT/IB2014/062978 patent/WO2015004616A1/en not_active Ceased
- 2014-07-09 RU RU2016104397A patent/RU2676274C2/ru not_active IP Right Cessation
- 2014-07-09 JP JP2016524930A patent/JP2016528202A/ja active Pending
- 2014-07-09 MX MX2016000384A patent/MX2016000384A/es unknown
- 2014-07-09 CA CA2917807A patent/CA2917807A1/en not_active Abandoned
- 2014-07-09 EP EP14741406.4A patent/EP3019526A1/en not_active Withdrawn
-
2017
- 2017-06-09 AU AU2017203923A patent/AU2017203923B2/en not_active Ceased
-
2018
- 2018-02-27 US US15/906,421 patent/US20180194835A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016528202A5 (enExample) | ||
| RU2016104397A (ru) | Применение антагониста vegf при лечении хориоретинальных неоваскулярных нарушений и нарушений проницаемости у педиатрических пациентов | |
| JP2016530280A5 (enExample) | ||
| JP2015528454A5 (enExample) | ||
| HRP20211453T1 (hr) | Liječenje amd uporabom aav sflt-1 | |
| MX2017012506A (es) | Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan. | |
| JP2016065094A5 (enExample) | ||
| JP2016523956A5 (enExample) | ||
| MX349901B (es) | Uso de un antagonista de factor de crecimiento endotelial vascular para tratar transtornos oculares angiogenicos. | |
| RU2017119647A (ru) | Способ лечения болезней глаз | |
| JP2015525798A5 (enExample) | ||
| RU2015117536A (ru) | Vegf-нейтрализирующие пролекарства для лечения офтальмологических заболеваний | |
| JP2016528247A5 (enExample) | ||
| JP2012525415A5 (enExample) | ||
| KR102373289B1 (ko) | 지속성 부종을 갖는 삼출성 노인성 황반변성을 치료하기 위한 시롤리무스의 용도 | |
| JP2016521712A5 (enExample) | ||
| JP2017503014A5 (enExample) | ||
| JP2016516016A5 (enExample) | ||
| JP2019530713A5 (enExample) | ||
| JP2017523974A5 (enExample) | ||
| JP2017533201A5 (enExample) | ||
| JP2016027060A5 (enExample) | ||
| JP2018521643A5 (enExample) | ||
| JP2017534645A5 (enExample) | ||
| JP2019535651A5 (enExample) |